EveryONE Medicines develops nucleic acid therapeutics targeting pathogenic genetic mutations in patients with rare diseases. By focusing on the genetic origins of these conditions, the company aims to provide effective treatments for the approximately 78% of rare diseases that currently lack approved therapies.
Funding
Funding not disclosed
Founders
Product
Problem
Many rare diseases lack effective treatments, particularly those with a genetic origin, leaving a significant portion of affected individuals without approved therapeutic options. Identifying the specific genetic mutations responsible for these conditions can be challenging, hindering the development of targeted therapies.
Solution
EveryONE Medicines is developing nucleic acid therapeutics designed to address pathogenic genetic mutations in patients suffering from rare diseases. By targeting the root genetic causes of these conditions, the company aims to create effective treatments for a substantial portion of the rare disease population that currently lacks approved therapies. Their approach focuses on precision medicine, tailoring treatments to the unique genetic profiles of individual patients to maximize therapeutic efficacy. The company leverages genome sequencing to identify specific mutations and design corresponding nucleic acid-based interventions.
Target Audience
The primary target audience includes patients diagnosed with rare diseases of genetic origin and the healthcare providers who treat them.
Features
- Development of nucleic acid therapeutics targeting specific pathogenic genetic mutations.
- Focus on rare diseases with unmet medical needs and a genetic origin.
- Utilization of genome sequencing to identify targetable mutations.
- Precision medicine approach to tailor treatments to individual patient genetics.